Letter to the Editor: Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer.
- Resource Type
- Letter
- Authors
- Groussin, Lionel; Bessiene, Laura; Arrondeau, Jennifer; Garinet, Simon; Cochand-Priollet, Béatrix; Lupo, Audrey; Zerbit, Jérémie; Clerc, Jérôme; Huillard, Olivier
- Source
- Thyroid. Oct2021, Vol. 31 Issue 10, p1603-1604. 2p.
- Subject
- *THYROID cancer
*IODINE isotopes
*COMPUTED tomography
*POSITRON emission tomography
*MITOGEN-activated protein kinases
- Language
- ISSN
- 1050-7256
A new diagnostic RAI scintigraphy performed 3 weeks after the initiation of selpercatinib (160 mg twice daily) showed restoration of RAI uptake. A therapeutic RAI dose was administered 2 weeks later and redifferentiation was confirmed on post-therapy scan with RAI uptake in all fluorine 18 fluorodeoxyglucose (18F-FDG) avid lesions. B Dear Editor: b Differentiated thyroid cancers have worse prognosis if the metastatic tissue is radioactive iodine (RAI)-refractory or loses the ability to take up iodine-131 ( SP 131 sp I). [Extracted from the article]